Skip to main content
Journal of Patient-Reported Outcomes

Table 2 Health status and utilization*

From: Use of the PROMIS-10 global health in patients with chronic low back pain in outpatient physical therapy: a retrospective cohort study

 

Total cohort

N = 328

PH-LOW group

N = 179

PH-HIGH group

N = 149

p valuea

MH-LOW group

N = 89

MH-HIGH group

N = 239

p valuea

PROMIS 10 PHb

39.8 (34.9, 44.9)

34.9 (29.6, 37.4)

47.7 (44.9, 50.8)

< .001

   

Excellent

5 (1.5)

0 (0.0)

5 (1.5)

    

Very good

40 (12.2)

0 (0.0)

40 (12.2)

    

Good

104 (31.7)

0 (0.0)

104 (31.7)

    

Fair

104 (31.7)

104 (31.7)

0 (0.0)

    

Poor

75 (22.9)

75 (22.9)

0 (0.0)

    

PROMIS 10 MHb

45.8 (38.8, 53.3)

   

33.8 (31.3, 36.3)

48.3 (45.8, 53.3)

< .001

Excellent

35 (10.7)

   

0 (0.0)

35 (10.7)

 

Very Good

127 (38.7)

   

0 (0.0)

127 (38.7)

 

Good

77 (23.5)

   

0 (0.0)

77 (23.5)

 

Fair

57 (17.4)

   

57 (17.4)

0 (0.0)

 

Poor

32 (9.8)

   

32 (9.8)

0 (0.0)

 

CCI scoreb

0 (0, 2)

1 (0, 2)

0 (0, 1)

< .001

1 (0, 3)

0 (0, 1)

< .001

0

168 (51.2)

67 (37.4)

101 (67.8)

 

25 (28.1)

143 (59.8)

 

1

76 (23.2)

45 (25.1)

31 (20.8)

 

27 (30.3)

49 (20.5)

 

2

37 (11.3)

27 (15.1)

10 (6.7)

 

13 (14.6)

24 (10.0)

 

3+

47 (14.3)

40 (22.3)

7 (4.7)

 

24 (27.0)

23 (9.6)

 

Comorbidities

Depression

123 (37.5)

81 (45.3)

42 (28.2)

.001

53 (59.6)

70 (29.3)

< .001

Diabetes

57 (17.4)

42 (23.5)

15 (10.1)

.001

27 (30.3)

30 (12.6)

< .001

Kidney disease

43 (13.1)

31 (17.3)

12 (8.1)

.013

23 (25.8)

20 (8.4)

< .001

MI

8 (2.4)

6 (3.4)

2 (1.3)

.240

5 (5.6)

3 (1.3)

.023

CHF

22 (6.7)

19 (10.6)

3 (2.0)

.002

9 (10.1)

13 (5.4)

.132

PVD

29 (8.8)

22 (12.3)

7 (4.7)

.016

9 (10.1)

20 (8.4)

.621

CVD

31 (9.5)

24 (13.4)

7 (4.7)

.007

11 (12.4)

20 (8.4)

.272

Dementia

3 (0.9)

3 (1.7)

0 (0)

.112

2 (2.2)

1 (0.4)

.122

COPD

80 (24.4)

54 (30.2)

26 (17.4)

.008

34 (38.2)

46 (19.2)

< .001

Rheumatic disease

15 (4.6)

11 (6.1)

4 (2.7)

.135

5 (5.6)

10 (4.2)

.580

Peptic ulcer disease

13 (4.0)

10 (5.6)

3 (2.0)

.099

6 (6.7)

7 (2.9)

.116

Liver disease

40 (12.2)

31 (17.3)

9 (6.0)

.002

19 (21.3)

21 (8.8)

.002

Paraplegia

4 (1.2)

4 (2.2)

0 (0.0)

.066

2 (2.2)

2 (0.8)

.301

Physical therapy utilization

Physical therapy visitsb

3 (2, 6)

3 (1, 6)

3 (2, 6)

.523

3 (1, 6)

4 (2, 6)

.043

Cancellations or no-showsb

3 (2, 6)

3 (2, 7)

3 (1, 5)

.014

4 (2, 9.5)

3 (1, 5)

.008

Appointment lead time (days)b

21 (16, 27)

20 (15, 25)

22 (17, 28)

.031

19 (15, 25)

21 (16, 27.8)

.065

Prior utilization within 1 year

Opioids ordered

112 (34.1)

69 (38.5)

43 (28.9)

.065

35 (39.3)

7 7(32.2)

.227

Spine imaging ordered

99 (30.2)

49 (27.4)

50 (33.6)

.225

23 (25.8)

76 (31.8)

.296

Post utilization within 6 months

Opioids Ordered

25 (7.7)

18 (10.2)

7 (4.7)

.062

12 (14.0)

13 (5.4)

.011

Spine imaging ordered

40 (12.3)

30 (17.0)

10 (6.7)

.005

14 (16.3)

26 (10.9)

.191

Admittances

9 (2.8)

7 (4.0)

2 (1.3)

.149

4 (4.7)

5 (2.1)

.215

  1. *Values presented as N (%) unless stated otherwise
  2. PH: Physical Health; MH: Mental Health; CCI: Charlson Comorbidity Index; MI, myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease
  3. aDifference between subgroups
  4. bValues presented as median (IQR)
Back to article page